Zhuang Can, Xie Chun-guang, Chen Min, Liu Ya, Gao Hong
Medicine, Liuzhou Municipal Liutie Central Hospital, Guangxi 545007, China.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Mar;33(3):351-5.
To observe the effects of Shenqi Compound (SQC) on the mRNA expression of angiotensin II type 1 receptor (AT1R) in the aorta of Goto-Kakizaki (GK) rats.
Totally 67 GK rats were randomly divided into 5 groups, i.e., the GK group (n =18), the model group (n =16), the atorvastatin group (n =17), and the SQC group (n =16). Another a normal control group was set up (n =18). The diabetic macrovascular disease model was prepared by adding L-NAME (at the daily dose of 0.10 mg/mL) in drinking water for GK rats. GK rats, except those in the normal control group were fed with high fat diet. Atorvastatin (at the daily dose of 1.60 mg/kg) and SQC (at the daily dose of 1.44 g/kg) were respectively administered by gastrogavage, once daily for 35 successive days. The blood glucose was determined by glucose oxidase method once per week. After 5-week medication, the contents of triglyceride (TG) and total cholesterol (TC) were determined by ELISA. The serum concentrations of angiotensin I (Ang II) were determined by RIA. The mRNA expression of AT1R in the aorta was determined by real-time quantitative reverse transcriptase PCR (RT-PCR).
The blood glucose level was obviously lower in both the atorvastatin group and the SQC group after 4 weeks of medication (P <0.05). Besides, it was significantly lower in the SQC group than in the model group by the end of the 4th week (P <0.05). The concentrations of TG, TC and serum Ang II , and the mRNA expression of AT1R in the aorta were significantly higher in the model group than in the normal control group (P <0.01). After 5-week medication, the concentrations of TG, TC and serum Ang I , and the mRNA expression of AT1 R in the aorta were significantly lower in the atorvastatin group and the SQC group than in the model group (P <0.01, P <0.05). The mRNA expression of AT1R was significantly higher in the SQC group than in the atorvastatin group (P <0.05).
SQC could significantly reduce the levels of blood glucose, TG, TC, down-regulate the mRNA expression of AT1R in the aorta, and decrease the expressions of serum Ang II of GK rats with diabetic macrovascular disease. AT1 R might be one of effective targets of SQC in treating diabetic macrovascular diseases.
观察参芪复方（SQC）对戈托-崎崎（GK）大鼠主动脉血管紧张素II 1型受体（AT1R）mRNA表达的影响。
将67只GK大鼠随机分为5组，即GK组（n = 18）、模型组（n = 16）、阿托伐他汀组（n = 17）和SQC组（n = 16）。另设正常对照组（n = 18）。通过在GK大鼠饮用水中添加L-硝基精氨酸甲酯（L-NAME，每日剂量0.10 mg/mL）制备糖尿病大血管疾病模型。除正常对照组外，GK大鼠均喂以高脂饮食。阿托伐他汀（每日剂量1.60 mg/kg）和SQC（每日剂量1.44 g/kg）分别通过灌胃给药，连续35天，每日1次。每周用葡萄糖氧化酶法测定血糖1次。用药5周后，采用酶联免疫吸附测定法（ELISA）测定甘油三酯（TG）和总胆固醇（TC）含量。采用放射免疫分析法（RIA）测定血清血管紧张素I（Ang II）浓度。采用实时定量逆转录聚合酶链反应（RT-PCR）法测定主动脉中AT1R的mRNA表达。
用药4周后，阿托伐他汀组和SQC组血糖水平均明显降低（P < 0.05）。此外，在第4周结束时，SQC组血糖水平明显低于模型组（P < 0.05）。模型组主动脉中TG、TC和血清Ang II浓度以及AT1R的mRNA表达均显著高于正常对照组（P < 0.01）。用药5周后，阿托伐他汀组和SQC组主动脉中TG、TC和血清Ang I浓度以及AT1R的mRNA表达均显著低于模型组（P < 0.01，P < 0.05）。SQC组AT1R的mRNA表达显著高于阿托伐他汀组（P < 0.05）。
SQC可显著降低GK糖尿病大血管疾病大鼠的血糖、TG、TC水平及主动脉中AT1R的mRNA表达，降低血清Ang II水平。AT1R可能是SQC治疗糖尿病大血管疾病的有效靶点之一。
